340B Orphan Drug Exemption Ruling Opens Up Potential Area For Legislative Compromise
This article was originally published in RPM Report
On its second try, PhRMA wins the ruling it wanted on exempting products from 340B sales. The commercial impact won’t be huge – but it does give the 340B sector something it needs in a legislative fix.
Register for our free email digests: